Factors associated with first live birth and its competing event: total population and 2-year landmark population
| Time period . | 0-10 y . | P value . | 2-10 y . | P value . | 0-10 y . | P value . | 2-10 y . | P value . |
|---|---|---|---|---|---|---|---|---|
| Event . | First live birth RR (95%CI) . | First live birth RR (95%CI) . | Competing event RR (95%CI) . | Competing event RR (95%CI) . | ||||
| Intercept (baseline hazard) | 0.02 (0.006-0.04) | <.001 | 0.02 (0.006-0.07) | <.001 | 0.09 (0.07-0.11) | <.001 | 0.02 (0.008-0.03) | <.001 |
| Patient age, reference: 18-25 y | ||||||||
| Increase by 1 category | 0.36 (0.24-0.51) | <.001 | 0.37 (0.23-0.54) | <.001 | 1.02 (0.97-1.1) | .41 | 1.01 (0.87-1.16) | .94 |
| TBI, reference: no TBI | ||||||||
| TBI <8 Gy | 0.63 (0.23-1.50) | .33 | 0.78 (0.26-2.11) | .64 | 1.06 (0.84-1.34) | .61 | 0.92 (0.45-1.75) | .80 |
| TBI ≥8 Gy | 0.31 (0.09-0.88) | .04 | 0.20 (0.03-0.80) | .04 | 0.91 (0.78-1.06) | .24 | 0.81 (0.53-1.22) | .32 |
| Missing information | 0.21 (0.03-0.73) | .03 | 0.12 (0.006-0.60) | .04 | 0.75 (0.59-0.93) | .01 | 0.50 (0.25-0.95) | .04 |
| Donor type, reference: identical sibling | ||||||||
| Alternative donor | 0.59 (0.33-1.11) | .09 | 0.75 (0.36-1.61) | .44 | 1.48 (1.28-1.71) | <.001 | 0.99 (0.70-1.44) | .99 |
| Conditioning with cyclophosphamide, reference: other | ||||||||
| Cyclophosphamide | 0.70 (0.35-1.43) | .33 | 0.58 (0.23-1.38) | .22 | 0.96 (0.84-1.11) | .612 | 1.03 (0.70-1.49) | .90 |
| Conditioning intensity, reference: myeloablative | ||||||||
| RIC/NMA | 2.42 (1.07-5.89) | .04 | 2.08 (0.77-6.14) | .16 | 1.15 (0.98-1.35) | .09 | 1.26 (0.81-1.94) | .30 |
| Diagnosis, reference: AML or MDS | ||||||||
| BM failure/hemoglobinopathy | 2.45 (1.09-5.42) | .03 | 3.24 (1.19-8.88) | .02 | 0.52 (0.37-0.70) | <.001 | 0.11 (0.006-0.51) | .03 |
| Diagnosis other | 1.00 (0.43-2.20) | .99 | 1.02 (0.37-2.58) | .97 | 0.83 (0.71-0.97) | .02 | 0.84 (0.55-1.25) | .40 |
| aGVHD, reference: none/grade 1 | ||||||||
| aGVHD grade 2-4 | — | — | 1.32 (0.50-3.12) | .55 | — | — | 1.35 (0.94-1.92) | .10 |
| aGVHD missing | — | — | 2.87 (0.16-15.10) | .32 | — | — | 0 | .97 |
| cGVHD, reference: none | ||||||||
| cGVHD yes | — | — | 1.04 (0.49-2.20) | .92 | — | — | 2.63 (1.77-4.00) | <.001 |
| Time period . | 0-10 y . | P value . | 2-10 y . | P value . | 0-10 y . | P value . | 2-10 y . | P value . |
|---|---|---|---|---|---|---|---|---|
| Event . | First live birth RR (95%CI) . | First live birth RR (95%CI) . | Competing event RR (95%CI) . | Competing event RR (95%CI) . | ||||
| Intercept (baseline hazard) | 0.02 (0.006-0.04) | <.001 | 0.02 (0.006-0.07) | <.001 | 0.09 (0.07-0.11) | <.001 | 0.02 (0.008-0.03) | <.001 |
| Patient age, reference: 18-25 y | ||||||||
| Increase by 1 category | 0.36 (0.24-0.51) | <.001 | 0.37 (0.23-0.54) | <.001 | 1.02 (0.97-1.1) | .41 | 1.01 (0.87-1.16) | .94 |
| TBI, reference: no TBI | ||||||||
| TBI <8 Gy | 0.63 (0.23-1.50) | .33 | 0.78 (0.26-2.11) | .64 | 1.06 (0.84-1.34) | .61 | 0.92 (0.45-1.75) | .80 |
| TBI ≥8 Gy | 0.31 (0.09-0.88) | .04 | 0.20 (0.03-0.80) | .04 | 0.91 (0.78-1.06) | .24 | 0.81 (0.53-1.22) | .32 |
| Missing information | 0.21 (0.03-0.73) | .03 | 0.12 (0.006-0.60) | .04 | 0.75 (0.59-0.93) | .01 | 0.50 (0.25-0.95) | .04 |
| Donor type, reference: identical sibling | ||||||||
| Alternative donor | 0.59 (0.33-1.11) | .09 | 0.75 (0.36-1.61) | .44 | 1.48 (1.28-1.71) | <.001 | 0.99 (0.70-1.44) | .99 |
| Conditioning with cyclophosphamide, reference: other | ||||||||
| Cyclophosphamide | 0.70 (0.35-1.43) | .33 | 0.58 (0.23-1.38) | .22 | 0.96 (0.84-1.11) | .612 | 1.03 (0.70-1.49) | .90 |
| Conditioning intensity, reference: myeloablative | ||||||||
| RIC/NMA | 2.42 (1.07-5.89) | .04 | 2.08 (0.77-6.14) | .16 | 1.15 (0.98-1.35) | .09 | 1.26 (0.81-1.94) | .30 |
| Diagnosis, reference: AML or MDS | ||||||||
| BM failure/hemoglobinopathy | 2.45 (1.09-5.42) | .03 | 3.24 (1.19-8.88) | .02 | 0.52 (0.37-0.70) | <.001 | 0.11 (0.006-0.51) | .03 |
| Diagnosis other | 1.00 (0.43-2.20) | .99 | 1.02 (0.37-2.58) | .97 | 0.83 (0.71-0.97) | .02 | 0.84 (0.55-1.25) | .40 |
| aGVHD, reference: none/grade 1 | ||||||||
| aGVHD grade 2-4 | — | — | 1.32 (0.50-3.12) | .55 | — | — | 1.35 (0.94-1.92) | .10 |
| aGVHD missing | — | — | 2.87 (0.16-15.10) | .32 | — | — | 0 | .97 |
| cGVHD, reference: none | ||||||||
| cGVHD yes | — | — | 1.04 (0.49-2.20) | .92 | — | — | 2.63 (1.77-4.00) | <.001 |
Results from Poisson regression modeling for the competing risk setting: first live birth and its competing event death without previous first live birth. We show incidence RRs. Values >1 indicate an increased chance/risk for this event; values <1 indicate a reduced chance/risk for this event. Age categories (18-25 years, 25-30 years, 30-35 years, and 35-40 years) were evaluated as continuous covariates. Results indicate changes in event rates from 1 category to the next higher category.
Boldface P values represent statistical signficance at a level <5%. Italicized text represents the calculations for the 2-year landmark analysis.
AML, acute myeloid leukemia; BM, bone marrow; CI, confidence interval; MDS, myelodysplastic syndrome.